Michael Barbella, Managing Editor10.17.23
Inspira Technologies OXY B.H.N. Ltd. has concluded a usability study in Boston for its INSPIRA ART100 device.
The usability study included U.S. healthcare professionals who participated in testing and examining the INSPIRA ART100 in a setting designed to consider human factors of the intended users, uses and use environments.
“We are advancing with the INSPIRA ART100. We plan to take a position in disrupting the medical device industry with our technology,” Inspira Technologies CEOfficer Dagi Ben Noon stated.
The INSPIRA ART100 is an extracorporeal blood circulation medical device designed for cardiac and pulmonary support, by providing continuous enrichment of the blood with oxygen and carbon dioxide removal. The INSPIRA ART100 may be suitable for a wide range of extracorporeal treatments in the ICU and during heart surgery.
Inspira Technologies develops medical technologies and products that prevent the need for mechanical ventilation. Empowering breathing without lungs, the flagship INSPIRATM ART500 is designed to boost blood oxygen saturation levels in a matter of minutes, even as the patient remains awake. The company strives to deliver blood circulation technology alongside artificial intelligence-driven monitoring and analytics to create patient-centric and data-driven solutions that enhance patient outcome and improve hospital efficiency. Inspira Technologies' products have not yet been tested or used in humans and have not been approved by any regulatory body.
The usability study included U.S. healthcare professionals who participated in testing and examining the INSPIRA ART100 in a setting designed to consider human factors of the intended users, uses and use environments.
“We are advancing with the INSPIRA ART100. We plan to take a position in disrupting the medical device industry with our technology,” Inspira Technologies CEOfficer Dagi Ben Noon stated.
The INSPIRA ART100 is an extracorporeal blood circulation medical device designed for cardiac and pulmonary support, by providing continuous enrichment of the blood with oxygen and carbon dioxide removal. The INSPIRA ART100 may be suitable for a wide range of extracorporeal treatments in the ICU and during heart surgery.
Inspira Technologies develops medical technologies and products that prevent the need for mechanical ventilation. Empowering breathing without lungs, the flagship INSPIRATM ART500 is designed to boost blood oxygen saturation levels in a matter of minutes, even as the patient remains awake. The company strives to deliver blood circulation technology alongside artificial intelligence-driven monitoring and analytics to create patient-centric and data-driven solutions that enhance patient outcome and improve hospital efficiency. Inspira Technologies' products have not yet been tested or used in humans and have not been approved by any regulatory body.